CN105213770A - A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine - Google Patents
A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine Download PDFInfo
- Publication number
- CN105213770A CN105213770A CN201510631398.3A CN201510631398A CN105213770A CN 105213770 A CN105213770 A CN 105213770A CN 201510631398 A CN201510631398 A CN 201510631398A CN 105213770 A CN105213770 A CN 105213770A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginsenoside
- chinese medicine
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to technical field of Chinese medicines, relate to a kind of Chinese medicine composition for the preparation of the purposes in treatment myocardial infarction medicine.This Chinese medicine composition is prepared from by the raw material of following parts by weight: Radix Ophiopogonis 6-15 part, Radix Angelicae Sinensis 4-10 part, Eupolyphaga Seu Steleophaga 4-10 part, ginsenoside Rb1? 1-10 part, ginsenoside Rg1? 1-10 part, ginsenoside Rd? 1-5 part, ginsenoside Re? 1-5 part, Rhizoma Chuanxiong 3-10 part, Cortex Cinnamomi 3-10 part and Radix Glycyrrhizae 1-10 part.The Chinese medicine composition that the present invention relates to has effect of removing blood stasis, invigorating the spleen and replenishing QI and heat-clearing and toxic substances removing, also has that preparation technology is simple, good effect, side effect are low, taking convenience and be easy to advantages such as applying.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of Chinese medicine composition for the preparation of the purposes in treatment myocardial infarction medicine.
Background technology
Myocardial infarction is the disease of the part myocardial necrosis caused due to the lasting severe ischemic of cardiac muscle, multiple be born in the middle age after, have the symptom such as the similar anginal front chest pain of violent and lasting character, cardiopalmus, asthma, weak and faint pulse, blood pressure reduction during morbidity.Primary disease incidence rate has and increases trend year by year, and arteriosclerosis accounts for 98% of Pathogenesis of Acute Myocardial Infarction rate, and patient more than 40 years old is in the majority, and many with hypertension, and nearly half is angor medical history intentionally.
In treatment, be broadly divided into two classes: one is take stopgap measures and effect a permanent cure, i.e. " symptomatic treatment in acute condition, radical treatment in chronic case "; Two is routine treatment and contrary treatment, i.e. " treating with drugs opposite to the nature of disease is called routine treatment, contrary treatment means that the remedy coincides with the pseudo-symptom of disease ", and the one that routine treatment is its syndrome character inverse and controls commonly uses therapeutic rules, and contrary treatment is a kind of Therapeutic Method of being obedient to disease illusion and controlling.The present traditional Chinese medical science thinks that the main pathogenesis of coronary heart disease myocardial infarction is deficiency in origin and excess in superficiality, and deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN, and mark is real turbid common with the stagnation of QI, blood stasis, expectorant.The ancient prescription traditional Chinese medical science proposes phlegm and blood stasis theory, thinks body fluid transporting mistake department, stops poly-ly forming expectorant; Escape of blood from meridians, stays in arteries and veins outer or stagnant in arteries and veins, causes blood stasis expectorant to stop or expectorant is poly-hinders blood; Or the expectorant stasis of blood is changed mutually, stagnant in passages through which vital energy circulates to expectorant stasis blocking eventually, phlegm and blood stasis and causing a disease; And myocardial infarction be divided into type of deficiency of both QI and YIN, deficiency of YANG QI weak type, the expectorant stasis of blood to hand over three types such as resistance qi stagnation and blood stasis type, control respectively with supplementing QI and nourishing YIN, QI invigorating warming YANG, dissipating phlegm and removing blood stasis.
Chinese patent application 201410113088.8 discloses a kind of Chinese medicine composition for the treatment of myocardial infarction, its raw materials comprises: Galla Chinensis, Flos Lonicerae, the Cortex Eucommiae, Radix Cirsii Japonici, Rhizoma Chuanxiong, Radix Rehmanniae, Periostracum Cicadae, Poria, the Radix Paeoniae Alba, Radix Codonopsis and Radix Glycyrrhizae, this Chinese medicine composition has good therapeutic effect in treatment myocardial infarction, there is significant clinical generalization value, but the effect in supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling etc. not very remarkable.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition for the preparation of the purposes in treatment myocardial infarction medicine, this Chinese medicine composition has effect of removing blood stasis, invigorating the spleen and replenishing QI and heat-clearing and toxic substances removing, also have that preparation technology is simple, good effect, side effect be low, taking convenience and be easy to advantages such as applying, in addition, the present invention also provides corresponding manufacturing process to be made and facilitate easy-to-use preparation under the prerequisite ensureing curative effect by this pharmaceutical composition.
The Chinese medicine composition that the present invention relates to comprises the raw material of following parts by weight: Radix Ophiopogonis 6-15 part, Radix Angelicae Sinensis 4-10 part, Eupolyphaga Seu Steleophaga 4-10 part, ginsenoside Rb1 1-10 part, ginsenoside Rg1 1-10 part, ginsenoside Rd 1-5 part, ginsenoside Re 1-5 part, Rhizoma Chuanxiong 3-10 part, Cortex Cinnamomi 3-10 part and Radix Glycyrrhizae 1-10 part.
Preferably, described Chinese medicine composition comprises the raw material of following parts by weight: Radix Ophiopogonis 6 parts, Radix Angelicae Sinensis 10 parts, Eupolyphaga Seu Steleophaga 6 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 2 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Chuanxiong 6 parts, Cortex Cinnamomi 3 parts and 8 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition comprises the raw material of following parts by weight: Radix Ophiopogonis 15 parts, Radix Angelicae Sinensis 4 parts, Eupolyphaga Seu Steleophaga 4 parts, ginsenoside Rb1 2 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 3 parts, ginsenoside Re 2 parts, Rhizoma Chuanxiong 3 parts, Cortex Cinnamomi 8 parts and 3 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition comprises the raw material of following parts by weight: Radix Ophiopogonis 10 parts, Radix Angelicae Sinensis 6 parts, Eupolyphaga Seu Steleophaga 8 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 5 parts, ginsenoside Rd 1 part, ginsenoside Re 5 parts, Rhizoma Chuanxiong 10 parts, Cortex Cinnamomi 5 parts and 5 parts, Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
Accordingly, the preparation method of described Chinese medicine composition comprises following step:
A) Radix Ophiopogonis is taken, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30-45% is the alcoholic solution of 60-85%, and regulation and control carbon dioxide flow is 15-20L/h, and extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, extraction time is 1.5-2h, and decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis;
B) take Radix Angelicae Sinensis, Eupolyphaga Seu Steleophaga, Rhizoma Chuanxiong, Cortex Cinnamomi and Radix Glycyrrhizae, add residue described Radix Ophiopogonis, be ground into coarse powder, doubly add according to the 3-8 of coarse powder gross weight the alcoholic solution that volumetric concentration is 60%-90%, reflux, extract, 1-2 time, return time is 2-5h, filter, obtain filtrate;
C) described Radix Ophiopogonis extract and described filtrate are merged, add ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.20-1.30, dry, be ground into powder, obtain Chinese medicine composition.
Source, the nature and flavor of the present invention's component used, return through and effect:
Radix Ophiopogonis: be the tuber of liliaceous plant Radix Ophiopogonis, Hubei Radix Ophiopogonis, short Roripa mountain wheat or Radix Liriopes, dwarf lilyturf etc.; Sweet, micro-hardship, is slightly cold, GUIXIN, lung, stomach warp.YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire, and for dryness of the lung dry cough, chronic consumptive disease is coughed, and Tianjin wound is thirsty, and vexed insomnia, interior-heat is quenched one's thirst, dryness of the intestine constipation, pharyngeal diphtheria.Radix Ophiopogonis is containing cupreol, aminoacid, volume glucose and glycoside.Can immunologic function be improved, have inhibitory action to various bacteria, pituitary adrenal system function can be strengthened, improve organism adaptation ability, have arrhythmia and the peripheral vascular effect of expansion, can hypoxia-bearing capability be improved, have hypoglycemic activity.
Radix Angelicae Sinensis: this product is the dry root of umbelliferae angelica; Sweet in the mouth, pungent, warm in nature; Return liver, the heart, spleen channel; Enrich blood and invigorate blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.
Eupolyphaga Seu Steleophaga: this product is the female worm dry body of Corydiidae insecticide eupolyphoge sinensis; Salty in the mouth, cold in nature; Return Liver Channel; Removing blood stasis, reunion of fractured tendons and bones.
Ginsenoside Rb1: this product derives from the dry root of Araliaceae Radix Ginseng; The effects such as Radix Ginseng has strongly invigorating primordial QI, strengthening by means of tonics, and Fructus Alpiniae Oxyphyllae of calming the nerves, promotes the production of body fluid, and multiple arteries and veins is admittedly de-; Research shows, ginsenoside Rb1 has protective effect to rat acute injury of renal tubular, and can promote that rabbit cartilage cell is bred.
Ginsenoside Rg1: this product derives from the dry root of Araliaceae Radix Ginseng; Radix Ginseng, by increasing the synthesis of bone marrow DNA, RNA, protein and lipid, promotes medullary cell mitosis, has the function of hemopoietic; Ginsenoside Rg1 has the function promoting hemopoietic, also has the function of vital energy benefiting and the kidney invigorating.
Ginsenoside Rd: this product derives from the dry root of Araliaceae Radix Ginseng; There is strongly invigorating primordial QI, effect of strengthening by means of tonics.
Ginsenoside Re: this product derives from the dry root of Araliaceae Radix Ginseng; Its molecular formula is C48H82O18, and molecular weight is 947.14, has effect of the kidney invigorating benefit blood.
Rhizoma Chuanxiong: this product is the dry rhizome of samphire Rhizoma Chuanxiong; Acrid in the mouth, warm in nature; Return liver, gallbladder, pericardium channel; Blood-activating and qi-promoting, wind-expelling pain-stopping.
Cortex Cinnamomi: be the dry bark of canella Cortex Cinnamomi; Acrid in the mouth, sweet, extremely hot in nature; Return kidney, spleen, the heart, Liver Channel; Mend fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow.
Radix Glycyrrhizae: this product is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Compared with prior art, the present invention has following beneficial effect:
1, Chinese medicine composition of the present invention is compared with the conventional medicine of existing treatment myocardial infarction, in removing blood stasis, invigorating the spleen and replenishing QI and heat-clearing and toxic substances removing etc., have more remarkable efficacy.
2, compared with the chemicals of Current therapeutic myocardial infarction, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, efficiently solves the morbidity root of myocardial infarction.
3, the Chinese medicine composition that the present invention relates to also has that compatibility science, preparation technology are simple, good effect, side effect are low, taking convenience and be easy to advantages such as applying.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
embodiment 1
The Chinese medicine composition that the present invention relates to is prepared from by the raw material of following parts by weight: Radix Ophiopogonis 6 parts, Radix Angelicae Sinensis 10 parts, Eupolyphaga Seu Steleophaga 6 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 2 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Chuanxiong 6 parts, Cortex Cinnamomi 3 parts and 8 parts, Radix Glycyrrhizae.
Preparation method: take Radix Ophiopogonis, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 45% is the alcoholic solution of 75%, and regulation and control carbon dioxide flow is 20L/h, and extracting pressure is 20MPa, extraction temperature is 60 DEG C, extraction time is 2h, and decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis; Take Radix Angelicae Sinensis, Eupolyphaga Seu Steleophaga, Rhizoma Chuanxiong, Cortex Cinnamomi and Radix Glycyrrhizae, add residue described Radix Ophiopogonis, be ground into coarse powder, add according to 5 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 75%, reflux, extract, 2 times, return time is 4h, filters, obtains filtrate; Described Radix Ophiopogonis extract and described filtrate are merged, adds ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.25, dry, pulverize powdered, obtain Chinese medicine composition.Add starch, water, syrup, Pulvis Talci, mix homogeneously, tabletting, obtain the tablet of the embodiment of the present invention 1 Chinese medicine composition.
embodiment 2
The Chinese medicine composition that the present invention relates to is prepared from by the raw material of following parts by weight: Radix Ophiopogonis 15 parts, Radix Angelicae Sinensis 4 parts, Eupolyphaga Seu Steleophaga 4 parts, ginsenoside Rb1 2 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 3 parts, ginsenoside Re 2 parts, Rhizoma Chuanxiong 3 parts, Cortex Cinnamomi 8 parts and 3 parts, Radix Glycyrrhizae.
Preparation method: take Radix Ophiopogonis, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30% is the alcoholic solution of 80%, and regulation and control carbon dioxide flow is 15L/h, and extracting pressure is 15MPa, extraction temperature is 50 DEG C, extraction time is 2h, and decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis; Take Radix Angelicae Sinensis, Eupolyphaga Seu Steleophaga, Rhizoma Chuanxiong, Cortex Cinnamomi and Radix Glycyrrhizae, add residue described Radix Ophiopogonis, be ground into coarse powder, add according to 6 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 80%, reflux, extract, 2 times, return time is 5h, filters, obtains filtrate; Described Radix Ophiopogonis extract and described filtrate are merged, adds ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.30, dry, pulverize powdered, obtain Chinese medicine composition.Add glycerol, gelatin, mix homogeneously, then add alcoholic solution, make pellet, removing ethanol, dry, obtain the drop pill of the embodiment of the present invention 2 Chinese medicine composition.
embodiment 3
The Chinese medicine composition that the present invention relates to is prepared from by the raw material of following parts by weight: Radix Ophiopogonis 10 parts, Radix Angelicae Sinensis 6 parts, Eupolyphaga Seu Steleophaga 8 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 5 parts, ginsenoside Rd 1 part, ginsenoside Re 5 parts, Rhizoma Chuanxiong 10 parts, Cortex Cinnamomi 5 parts and 5 parts, Radix Glycyrrhizae.
Preparation method: take Radix Ophiopogonis, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 40% is the alcoholic solution of 70%, and regulation and control carbon dioxide flow is 18L/h, and extracting pressure is 15MPa, extraction temperature is 45 DEG C, extraction time is 2h, and decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis; Take Radix Angelicae Sinensis, Eupolyphaga Seu Steleophaga, Rhizoma Chuanxiong, Cortex Cinnamomi and Radix Glycyrrhizae, add residue described Radix Ophiopogonis, be ground into coarse powder, add according to 8 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 70%, reflux, extract, 2 times, return time is 3h, filters, obtains filtrate; Described Radix Ophiopogonis extract and described filtrate are merged, adds ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.20, dry, pulverize powdered, obtain Chinese medicine composition.Add lactose, mixing, stirs, and crosses No. six sieves, obtains the powder of the embodiment of the present invention 3 Chinese medicine composition.
the Chinese medicine composition that the present invention relates to is on the impact of myocardial infarction model rat
1, rat model is set up:
Select body weight 0.2kg-0.3kg male SD rat, lumbar injection 30mg/kg anaesthetized with pentobarbital rat.Back of the body position is fixed, and inhale ball (size is just in time enclosed within rat head) with more than half, with ALC-V8 type animal respirator, tidal volume 10ml/kg, respiratory frequency 40-50 time/min, respiratory quotient is 1:1.Chest unhairing, sterilization, longitudinally cuts skin 20mm along left mid-clavicular line, in the 4th, 5 intercostal blunt separation muscle layer, strut Intercostal muscle with curved hemostat and pleura enters thoracic cavity, cut off pericardium, gently press breast corridor, right side with middle finger, thumb pressure xiphoid-process bottom, extrude heart, be mark with great cardiac vein between left auricle and pulmonary conus, and under left auricle root, 2-3mm 6-0 hurtless measure suture passes left anterior descending coronary artery, depth of needle is about 0.5mm, ligation ramus descendens anterior arteriae coronariae sinistrae.Heart is sent back in thoracic cavity, extrude thoracic cavity gently, get rid of thoracic cavity air, layer-by-layer suture thoracic incision, close breast.Postoperative intramuscular injection penicillin three days prevention infection.If mice still has vital sign, then modeling success.
2, experimental technique:
Choose 48 SD rats, be divided into 6 groups at random, often organize 8, be respectively blank group, model group, positive controls, low dose group, middle dosage group and high dose group, go out outside blank matched group, modeling hands art is carried out to other group rats, after modeling success, blank group and normal saline corresponding to model group gavage, positive controls gavage FUFANG DANSHEN PIAN, after FUFANG DANSHEN PIAN is smashed to pieces, thin up becomes pasty state to carry out gastric infusion, low dose group, middle dosage group and high dose group be the Chinese medicine composition composition powders for preparing of gavage embodiment 3 respectively, pasty state is become to carry out gastric infusion powder thin up, concrete dosage is as shown in table 1.Gastric infusion is after two weeks, and by rat anesthesia, abdomen cardinal vein gets hematometry creatine phosphokinase (CPK), glutamic oxaloacetic transaminase, GOT (AST) and lactic acid dehydrogenase (LDH).
3, experimental result:
Table 1 Chinese medicine composition of the present invention is on the impact of myocardial infarction model rat
Note: compare with model group,
*p < 0.05,
*p < 0.01.
The creatine phosphokinase of myocardial infarction patient, glutamic oxaloacetic transaminase, GOT and lactic acid dehydrogenase all can significantly raise, this experiment is by the situation of change of the creatine phosphokinase of research myocardial infarction model rat, glutamic oxaloacetic transaminase, GOT and lactic acid dehydrogenase, and whether known experiment Chinese medicine composition has effective therapeutical effect for myocardial infarction.Result shows, compared with model group, CK, AST, LDH of high, medium and low dosage group all significantly reduce (P < 0.01), there is extremely significant difference, CK, AST, LDH of positive controls also all significantly reduce (P < 0.01) compared with model group, but effect is not so good as the effective of high, medium and low dosage group.Visible, Chinese medicine composition of the present invention effectively can reduce CK, AST, LDH value of rat, has significant effect for treatment myocardial infarction.
clinical observation on the therapeutic effect
1, case selection: in 400 routine myocardial infarction clinical volunteers patients, male patient 220 example, female patient 180 example, age bracket be 40-60 year, all patients all has typical myocardial infarction and faces symptom, and in sex, age, the course of disease no difference of science of statistics.
2, diagnostic criteria:
(1) typical myocardial ischemia symptom (chest pain or discomfort uncomfortable in chest);
(2) typical cardiac electrical figure change;
(3) Serum fibrosis markers raises.
3, efficacy assessment standard:
Cure: after drug administration, malaise symptoms disappears completely;
Effective: after drug administration, malaise symptoms alleviates or partial disappearance;
Invalid: after drug administration, malaise symptoms is unchanged;
Total effective rate=(cure+effectively)/total number of cases × 100%.
4, instructions of taking: 400 patients are divided into 4 groups at random, often organize 100 people, be respectively treatment A group, treatment B group, treatment C group and matched group, treatment A group, treatment B group, treatment component C do not take tablet, drop pill and the powder that the embodiment of the present invention 1,2,3 prepares, and serve on 1 month.Matched group takes FUFANG DANSHEN DIWAN (Tianjin Tasly Pharmaceutical Co., Ltd, the accurate word Z10950111 of traditional Chinese medicines), oral or sublingual administration, and 10 balls, 3 times on the one 4 weeks is a course for the treatment of.
5, therapeutic outcome: as shown in table 2.
table 2 therapeutic outcome
This test adopts FUFANG DANSHEN DIWAN as a control group, FUFANG DANSHEN DIWAN has blood circulation promoting and blood stasis dispelling, effect of regulating QI to relieve pain, by comparing with the therapeutic effect of the Chinese medicine composition that the present invention relates to, can find out the curative effect of the traditional Chinese medicine composition for treating myocardial infarction aspect that the present invention relates to.Make inventor surprisingly, the cure rate of Chinese medicine composition of the present invention reaches more than 80%, and total effective rate reaches more than 85%, far above cure rate and the total effective rate of matched group, wherein best with the therapeutic effect for the treatment of C group.Visible, the good effect of the Chinese medicine composition that the present invention relates to, cure rate is high, can be used as the drug use for the treatment of myocardial infarction.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (6)
1. Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine, and it is characterized in that, described Chinese medicine composition comprises the raw material of following parts by weight:
Radix Ophiopogonis 6-15 part, Radix Angelicae Sinensis 4-10 part, Eupolyphaga Seu Steleophaga 4-10 part, ginsenoside Rb1 1-10 part, ginsenoside Rg1 1-10 part, ginsenoside Rd 1-5 part, ginsenoside Re 1-5 part, Rhizoma Chuanxiong 3-10 part, Cortex Cinnamomi 3-10 part and Radix Glycyrrhizae 1-10 part.
2. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition comprises the raw material of following parts by weight:
Radix Ophiopogonis 6 parts, Radix Angelicae Sinensis 10 parts, Eupolyphaga Seu Steleophaga 6 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 2 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Chuanxiong 6 parts, Cortex Cinnamomi 3 parts and 8 parts, Radix Glycyrrhizae.
3. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition comprises the raw material of following parts by weight:
Radix Ophiopogonis 15 parts, Radix Angelicae Sinensis 4 parts, Eupolyphaga Seu Steleophaga 4 parts, ginsenoside Rb1 2 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 3 parts, ginsenoside Re 2 parts, Rhizoma Chuanxiong 3 parts, Cortex Cinnamomi 8 parts and 3 parts, Radix Glycyrrhizae.
4. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition comprises the raw material of following parts by weight:
Radix Ophiopogonis 10 parts, Radix Angelicae Sinensis 6 parts, Eupolyphaga Seu Steleophaga 8 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 5 parts, ginsenoside Rd 1 part, ginsenoside Re 5 parts, Rhizoma Chuanxiong 10 parts, Cortex Cinnamomi 5 parts and 5 parts, Radix Glycyrrhizae.
5. purposes as claimed in claim 1, it is characterized in that, described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
6. the purposes as described in as arbitrary in claim 1-4, it is characterized in that, the preparation method of described Chinese medicine composition comprises following step:
A) Radix Ophiopogonis is taken, be ground into coarse powder, be placed in supercritical carbon dioxide extraction apparatus, the volume fraction adding coarse powder weight 30-45% is the alcoholic solution of 60-85%, and regulation and control carbon dioxide flow is 15-20L/h, and extracting pressure is 15-20MPa, extraction temperature is 40-60 DEG C, extraction time is 1.5-2h, and decompression separation obtains Radix Ophiopogonis extract, retains residue Radix Ophiopogonis;
B) take Radix Angelicae Sinensis, Eupolyphaga Seu Steleophaga, Rhizoma Chuanxiong, Cortex Cinnamomi and Radix Glycyrrhizae, add residue described Radix Ophiopogonis, be ground into coarse powder, doubly add according to the 3-8 of coarse powder gross weight the alcoholic solution that volumetric concentration is 60%-90%, reflux, extract, 1-2 time, return time is 2-5h, filter, obtain filtrate;
C) described Radix Ophiopogonis extract and described filtrate are merged, add ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.20-1.30, dry, be ground into powder, obtain Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510631398.3A CN105213770A (en) | 2015-09-29 | 2015-09-29 | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510631398.3A CN105213770A (en) | 2015-09-29 | 2015-09-29 | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105213770A true CN105213770A (en) | 2016-01-06 |
Family
ID=54983282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510631398.3A Pending CN105213770A (en) | 2015-09-29 | 2015-09-29 | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213770A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814163A (en) * | 2005-11-23 | 2006-08-09 | 刘青云 | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method |
| CN101491636A (en) * | 2009-03-05 | 2009-07-29 | 常熟雷允上制药有限公司 | Medicine for treating cardiac arrhythmia and its preparation method |
| KR101270599B1 (en) * | 2009-05-21 | 2013-06-03 | (주) 엔유씨생활과건강 | Fermented red ginseng composition containing fermented red ginseng and medical plant extracts exhibiting antidiabetic activity |
-
2015
- 2015-09-29 CN CN201510631398.3A patent/CN105213770A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814163A (en) * | 2005-11-23 | 2006-08-09 | 刘青云 | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method |
| CN101491636A (en) * | 2009-03-05 | 2009-07-29 | 常熟雷允上制药有限公司 | Medicine for treating cardiac arrhythmia and its preparation method |
| KR101270599B1 (en) * | 2009-05-21 | 2013-06-03 | (주) 엔유씨생활과건강 | Fermented red ginseng composition containing fermented red ginseng and medical plant extracts exhibiting antidiabetic activity |
Non-Patent Citations (3)
| Title |
|---|
| "《中华人民共和国药典：2010年版.一部》" * |
| 《心血管康复医学杂志》 * |
| 《白求恩军医学院学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102100856A (en) | Nano traditional Chinese medicine for treating bronchial asthma and preparation technology | |
| CN102670961B (en) | Traditional Chinese medicine for treating middle and old aged habitual constipation | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN104958494A (en) | Application of medicinal composition in preparation of medicament for treating gynecological hemorrhage | |
| CN103735843A (en) | Medicine composition for treating diabetes | |
| CN105833011A (en) | Healthcare medicinal liquor | |
| CN105311492A (en) | Medicine for treating coronary atherosclerotic heart disease | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN105796685A (en) | Method for preparing traditional Chinese medicine composition for treating myocardial infarction | |
| CN104940279A (en) | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction | |
| CN105343808A (en) | Traditional Chinese medicine composition with weight reducing effect and preparation method of traditional Chinese medicine composition | |
| CN105412424A (en) | Pharmaceutical preparation containing argy wormwood leaves and having bowel relaxing function as well as preparation method of pharmaceutical preparation | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN105213770A (en) | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine | |
| CN104162127A (en) | Traditional Chinese medicinal preparation for curing heart failure | |
| CN105288037A (en) | Application of medicine composition for preparing medicine for treating myocardial infarction | |
| CN102319423B (en) | Health care product for treating habitual constipation caused by internal heat due to yin deficiency | |
| CN105079397A (en) | Application of traditional Chinese medicine composition to preparation of drugs for treating myocardial infarction | |
| CN108310207B (en) | Pharmaceutical composition for treating heart failure and preparation method thereof | |
| CN105213743A (en) | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |
|
| RJ01 | Rejection of invention patent application after publication |